The Board of directors of the company has approved the appointment of Internal Auditor for FY 2025-26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board, at its 28th April 2025 meeting, approved the audited financial results for the half year and full year ended 31st March 2025, along with an unmodified (clean) opinion from statutory auditor A Bafna & Associates. On a standalone basis, FY25 total income stood at Rs 6,719.91 lakh (vs Rs 7,094 lakh in FY24), but net profit jumped sharply to Rs 1,305.14 lakh from Rs 704.34 lakh, lifting EPS to Rs 11.35. On a consolidated basis (including newly acquired subsidiaries TNS Pharma, TLL Parenterals, TLL Herbal, TLL Elements and Trident Mediquip), total income surged to Rs 9,519.58 lakh and net profit rose to Rs 1,174.79 lakh (EPS Rs 10.27). The board also appointed DAC & Co., Chartered Accountants (FRN 137035W) as Internal Auditor for FY 2025-26. No investor complaints were pending.
Positive for shareholders — nearly doubled standalone net profit and strong consolidated earnings growth signal improving profitability, supported by a clean audit. The new subsidiary consolidation expands the revenue base, while the routine internal auditor change has no material governance implications.